Named Bioactive Compounds · Compound
Matairesinol
Moderate Evidencelignan3 PubMed Studies
Hermetica Superfood Encyclopedia
Matairesinol is a plant lignan found in flaxseeds and whole grains that acts as a phytoestrogen with anti-inflammatory properties. It may reduce vascular inflammation markers and shows anticancer potential through apoptosis induction and epithelial-mesenchymal transition suppression.
Matairesinol is a naturally occurring plant lignan (phytoestrogen) with a dibenzylbutyrolactone structure (C20H22O6), primarily found in flaxseed, sesame seeds, and plants from genera Schisandra and Arctium. It is extracted using solvent-based methods with ethanol or methanol, or produced through bioconversion from precursors like pinoresinol using engineered E. coli expressing specific enzymes (PLR and SDH).
No large-scale human randomized controlled trials or meta-analyses have been conducted on matairesinol as a monotherapy. Evidence is limited to one observational study (PMID: 19361969) showing correlations between dietary lignan intake and reduced vascular inflammation markers, with all other research confined to preclinical cancer models (PMIDs: 39297880, 41232730, 36802650, 35892941).
No clinically studied human dosages exist. Preclinical studies used 50-150 μM in cancer cell lines, while dietary intake from flaxseed provides approximately 1-10 mg/day matairesinol equivalents. No standardized extract forms have established clinical ranges. Consult a healthcare provider before starting any new supplement.
Matairesinol is a plant lignan (polyphenolic compound) classified as a phytoestrogen, not a macronutrient or primary micronutrient. It is not a source of protein, fat, carbohydrates, fiber, vitamins, or minerals in meaningful dietary quantities. As a bioactive compound, it occurs in trace concentrations in foods: highest in sesame seeds (~5–9 mg/100g dry weight), flaxseeds (~0.01–0.09 mg/100g), rye bran (~0.5–1.5 mg/100g dry weight), and smaller amounts in whole grains, berries, and certain vegetables. Typical dietary intake in Western populations is estimated at 0.1–0.5 mg/day. Matairesinol is a precursor lignan that undergoes gut microbiota-dependent conversion to the mammalian lignan enterolactone (and to a lesser extent enterodiol) via demethylation and dehydroxylation by colonic bacteria such as Blautia producta and Clostridium scindens. Bioavailability is highly variable (estimated 20–50% conversion efficiency) and is strongly dependent on gut microbiome composition. Enterolactone, the primary metabolite, is detectable in serum and urine and is considered the biologically active form responsible for most observed health associations. Matairesinol itself has a molecular weight of 358.39 g/mol and exhibits weak estrogenic and antioxidant activity in its unconverted form. No established Dietary Reference Intake (DRI) or Recommended Daily Allowance (RDA) exists for matairesinol.
Matairesinol functions as a selective estrogen receptor modulator (SERM), binding to both ERα and ERβ receptors with higher affinity for ERβ. It suppresses pro-inflammatory cytokines IL-6 and TNF-α through NF-κB pathway inhibition. The compound induces apoptosis in cancer cells by activating caspase cascades and inhibits epithelial-mesenchymal transition by downregulating Snail and Twist transcription factors.
Human evidence for matairesinol comes primarily from observational dietary studies showing associations with reduced vascular inflammation markers. One study (PMID: 19361969) found higher dietary lignan intake, including matairesinol, correlated with lower IL-6 and TNF-α levels in adults. Anticancer effects are limited to preclinical studies in cell cultures and animal models, with no human clinical trials available. The preliminary evidence suggests potential cardiovascular benefits, but controlled human studies are needed to establish therapeutic efficacy.
Matairesinol appears generally safe when consumed through food sources like flaxseeds and whole grains. As a phytoestrogen, it may theoretically interact with hormone-sensitive conditions or hormone replacement therapy, though specific interactions haven't been documented. Pregnant and breastfeeding women should exercise caution with concentrated supplements due to estrogenic activity. No serious adverse effects or drug interactions have been reported in the limited available research.
